BioSpace News Archive

CoreLink, LLC, a leading designer and manufacturer of spinal implant systems, today announced the introduction of the Oro™ Lateral Plate System designed for optimum versatility to treat patients suffering from degenerative disk disease, spondylolisthesis, trauma, or spinal deformities.

Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”), the world’s leading temperature-controlled logistics solutions company dedicated to the life sciences industry, today announced the launch of its Advanced Therapy Shipper™ product line for the regenerative medicine market.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled “Evaluating the Efficacy and Safety of Ampion to treat Adults with Pain Due to Severe Osteoarthritis of the Knee”, today announced that Cooley LLP has been engaged to represent Ampio with respect to a potential strategic transaction, as well as related matters

HED, a national integrated design and engineering firm, is pleased to announce the completion of the new Max and Debra Ernst Heart Center at Beaumont Hospital, in Royal Oak, Michigan in the Detroit metro area.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Renato Skerlj, Ph.D., as Senior Vice President, Research and Development.

Medecision, an integrated health management solutions company that supports the health and care of more than 50 million consumers nationwide, is excited to announce the formation of its Advisory Board.

Animal models are essential tools in radiotherapy research that have played critical roles in developing our understanding of tumor and normal tissue response.

The global CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) market size will grow by USD 720.39 million during 2019-2023. This market report provides a detailed analysis of the market by type (monotherapy and combination therapy) and geography (Asia, Europe, North America, and ROW).

Analyst Confirms PURA Speculative BUY and $0.25 PPS Target

Olympus Commits to Open Dialogue, Unconscious Bias Education, Collaboration with Other Corporate Leaders and the Creation of Strategic Diversity and Inclusion Paths